Dr Agarwals Eye Hospital Q1FY27: Profit +35%

Why Dr Agarwals’ Q1 print matters

Dr Agarwals Eye Hospital reported a strong start to FY27, posting higher revenue and profit for the quarter ended June 30, 2026 (Q1FY27). Standalone net profit rose 35% year-on-year to ₹23.38 crore, supported by a 22% increase in revenue from operations to ₹142.97 crore. EBITDA also increased to ₹45.22 crore, although the information set notes a slight compression in margins. The numbers place the company firmly in focus during the June-quarter results season. Separately, the company has a board meeting and an earnings call scheduled on August 4, 2026 to consider and discuss the Q1FY27 unaudited results.

Q1FY27 revenue: broad-based top-line expansion

Revenue from operations increased to ₹142.97 crore in Q1FY27 from ₹116.92 crore in Q1FY26. The year-on-year growth of 22.28% reflects a broad-based expansion as described in the information set. The reported growth translated into operating leverage at the EBITDA line, even as margins were indicated to be slightly lower. For investors, the revenue trajectory is a key input given the company’s wider growth narrative cited for FY26.

EBITDA rises to ₹45.22 crore, margins noted lower

EBITDA climbed to ₹45.22 crore in Q1FY27 from ₹37.93 crore in Q1FY26, marking a 19.22% year-on-year increase. The update also flags a slight margin compression, but it does not provide the margin percentage for Q1FY27 in the standalone results summary. Even with this caveat, the absolute EBITDA improvement suggests that growth in operations supported higher operating earnings. The extent to which this margin movement is structural or temporary is not specified in the provided data.

Net profit up 35% to ₹23.38 crore

Net profit after tax (PAT) rose to ₹23.38 crore in Q1FY27 versus ₹17.26 crore in Q1FY26, a 35.46% increase. The improvement in PAT outpaced the growth in revenue and EBITDA in this quarter’s comparison set. The information set attributes the rise to the higher revenue base and improved earnings profile. No additional segment-level split is provided in the text.

Tax and PBT snapshot for the quarter

The effective tax rate was described as stable in the dataset. Total tax expense in Q1FY27 was ₹7.58 crore, against profit before tax (PBT) of ₹30.96 crore. These figures help explain the bridge between operating performance and the final PAT number. Beyond this, the dataset does not provide other line-item details such as finance costs or depreciation for the standalone quarter.

EPS improves to ₹48.38

Earnings per share (basic) increased to ₹48.38 in Q1FY27 from ₹36.72 in Q1FY26, a 31.75% rise. The EPS growth is presented as reflecting improved value creation for shareholders. The dataset does not specify the share count or any corporate actions affecting EPS. Still, the year-on-year comparison in reported EPS is consistent with the rise in PAT.

FY26 backdrop: income crossed ₹2,125 crore

The information set highlights a strong FY26 performance at the consolidated level. Total income for FY26 rose 20.9% year-on-year to ₹2,125 crore, and profit after tax increased 52.4% to ₹168 crore. Operating IndAS EBITDA reached ₹614 crore, with operating margins improving by 31 basis points to 28.9%. It also notes an approximately ₹30 crore loss from newly established greenfield branches during FY26, which affected margins. One-time expenditures linked to a merger process and relocation of the corporate office were cited as influencing Q4 outcomes.

Q1FY27 estimates: Uniresearch bands and targets

Alongside the reported standalone quarter numbers, the dataset includes a separate Uniresearch estimate set for Q1FY27. It lists a revenue estimate range of ₹565-650 crore based on a Q1FY26 base of ₹501 crore and presents a PAT estimate range of ₹39-50 crore versus ₹38 crore in Q1FY26. The table in the dataset shows +21.2% year-on-year growth for revenue and +17.4% for PAT using that base. A 12-month target range of ₹551-613 is also listed as an estimate. The dataset also notes that Q1FY27 results are expected in the July-August 2026 window, but separately mentions an “upcoming earnings date” of May 21, 2026 without clarifying the period.

Board meeting, earnings call, and trading window rules

The company has scheduled a board meeting for August 4, 2026 to evaluate and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. An earnings conference call for analysts and investors is scheduled the same day at 5:30 PM IST. The dataset also states that the trading window for dealing in the company’s shares is closed from June 30, 2026 until 48 hours after the public disclosure of the results. These timelines matter for market participants tracking the official release and management commentary.

Market snapshot: price points and valuation cues from the dataset

The information pack includes multiple price references around the results window, including CMP of ₹482.2 and another line citing ₹478.95 as the current share price. It also lists a market cap of ₹14,266 and a P/E of 111.9. Because the dataset contains multiple price snapshots, readers should treat them as point-in-time references from the same information set rather than a single definitive close. The text also mentions a “neutral directional bias” ahead of the August 4, 2026 board meeting and conference call.

Key numbers at a glance

What to track next

The August 4, 2026 board meeting and earnings call are the next formal checkpoints, as they cover both standalone and consolidated unaudited results for Q1FY27. Investors typically look for consistency between the reported headline growth and any commentary on margins, costs, and the pace of expansion. The dataset signals margin pressure in the quarter but does not quantify it for Q1FY27, making management commentary on operating trends an important pending input. Additionally, the presence of estimate bands and multiple date references in the dataset underscores the need to rely on the company’s official filings and disclosures for the final timeline.

Conclusion

Dr Agarwals Eye Hospital’s Q1FY27 standalone performance showed revenue from operations rising to ₹142.97 crore and PAT increasing to ₹23.38 crore, with EBITDA improving to ₹45.22 crore year-on-year. The next key event is the August 4, 2026 board meeting and the 5:30 PM IST earnings call, where the company is expected to approve and discuss the quarter’s unaudited results.